Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Companyâ€™s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

Employees

Sector

Pharmaceuticals

Calendar

08-25 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-08-17	SEK 65.00	-1.81%	10,653
26-08-14	SEK 66.20	-1.93%	9,955
26-08-13	SEK 67.50	+3.85%	4,081
26-08-12	SEK 65.00	0.00%	5,652
26-08-11	SEK 65.00	0.00%	3,408

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Stockholm 12:00:00 2026-08-17 EDT			5-day change	1st Jan Change
65.00 ^SEK	-1.81%		0.00%	+28.71%

07-07	Biovica International Names Chief Financial Officer	MT
07-07	Infant Bacterial Therapeutics CFO to Depart	MT

Market Cap	876M 92.23M 79.62M 74.7M 68.03M 128M 8.82B 130M 343M 4.42B 346M 339M 14.7B	P/E 2024	-5.27x	P/E 2025	-10.4x
Enterprise Value	732M 77.06M 66.53M 62.41M 56.85M 107M 7.37B 108M 287M 3.69B 289M 283M 12.28B	EV / Sales 2024	124,670,028,000x	EV / Sales 2025	-
Free-Float	79.71%	Yield 2024 *	-	Yield 2025	-

07-07	Biovica International Names Chief Financial Officer	MT
07-07	Infant Bacterial Therapeutics CFO to Depart	MT
07-07	IBT's CFO to step down in October	FW
07-07	IBT says CFO is leaving	FW
07-07	Maria Ekdahl to Leave as CFO of Infant Bacterial Therapeutics AB on October 7, 2026	CI
05-06	IBT reports widened operating loss	FW
05-06	IBT reports Q1 operating loss of SEK -23.5 million (-17.5)	FW
05-06	Infant Bacterial Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-03	Infant Bacterial announces phase III IBP-9414 study results	RE
03-03	IBT: Phase III Results Published in Pediatric Research	FW
02-06	Infant Bacterial Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-06	Infant Bacterial Therapeutics Q4 operating loss SEK 20.5 mln	RE
02-06	Infant Bacterial Therapeutics Q4 operating loss narrows to SEK 20.54 mln	RE

25-10-13	Infant Bacterial Therapeutics AB Announces Drug Candidate IBP-9414 Continues in the US and Europe	CI
24-09-04	IBT teleconference positive for the odds of IBP-9414 being approved (R)	FW
24-09-04	Positive odds for IBP-9414 to be approved	FW
24-09-02	SEB still sees huge upside in IBT despite study failure	FW
24-09-02	SEB lowers target price for IBT to SEK 330 (450), reiterates Buy	FW

Infant Bacterial Therapeutics AB Stock

Stocks

IBT B

SE0008015259

Pharmaceuticals

Valuation: Infant Bacterial Therapeutics AB

Chart: Infant Bacterial Therapeutics AB

Latest news : Infant Bacterial Therapeutics AB

Analysts' recommendations: Infant Bacterial Therapeutics AB

Press Releases: Infant Bacterial Therapeutics AB

Quotes and Performance

Course Extremes

Managers and Directors: Infant Bacterial Therapeutics AB

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

07-07	Biovica appoints Maria Ekdahl as new Chief Financial Officer	AQ
07-07	Infant Bacterial Therapeutics : CFO Leaves the Company	PU
05-07	Annual General Meeting of Infant Bacterial Therapeutics	AQ
04-02	Notice of Annual General Meeting of Infant Bacterial Therapeutics	AQ
03-30	Notice of Annual General Meeting of Infant Bacterial Therapeutics	AQ

1 day	-1.36%
Current month	-2.99%
1 month	-0.15%
3 months	+19.05%
6 months	+16.91%
Current year	+28.71%

1 week	64	67.6
1 month	63.3	69.4
Current year	44.75	71.9
1 year	43.25	84.3
3 years	21.7	135
5 years	21.7	135
10 years	21.7	274.5

Manager	Title	Age	Since
Staffan Strömberg CEO	Chief Executive Officer	59	2012-12-31
Maria Ekdahl DFI	Director of Finance/CFO	53	2022-09-18
Sanjiv Sharma CTO	Chief Tech/Sci/R&D Officer	70	-

Director	Title	Age	Since
Peter Michael Rothschild CHM	Chairman	76	2010-12-31
Margareta Hagman BRD	Director/Board Member	60	2015-09-23
Eva Idén BRD	Director/Board Member	60	2017-05-03

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/25/25	Staffan Strömberg	Free	Chief Executive Officer	65,000	0.4993%
9/25/25	Erik Anders Kronström	Free	Chief Operating Officer	32,500	0.2497%
9/25/25	Maria Ekdahl	Free	Chief Financial Officer	32,500	0.2497%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INFANT BACTERIAL THERAPEUTICS AB	-1.81%	0.00%	+25.24%	-28.88%	93.78M
MERCK & CO., INC.	+0.07%	+3.84%	+61.42%	+24.82%	335B
MERCK KGAA	+0.07%	-4.95%	+23.16%	-14.86%	68.61B
HALOZYME THERAPEUTICS, INC.	+4.26%	-0.19%	+48.52%	+141.10%	11.2B
KYOWA KIRIN CO., LTD.	-1.47%	-0.20%	-3.48%	-4.26%	8.49B
SK BIOPHARMACEUTICALS CO., LTD.	-0.34%	+2.22%	-13.22%	-7.03%	4.84B
YUHAN CORPORATION	+1.45%	+3.85%	-26.84%	+18.44%	4.42B
BETTA PHARMACEUTICALS CO., LTD.	+1.40%	-0.80%	+2.23%	+47.88%	4.28B
SUPERNUS PHARMACEUTICALS, INC.	+0.21%	+2.14%	+11.83%	+59.08%	2.81B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.60%	-3.43%	-5.51%	-3.09%	2.19B
Average	+0.32%	-0.24%	+12.34%	+23.32%	44.21B
Weighted average by Cap.	+0.13%	+3.42%	+50.98%	+20.93%

	2024	2025
Net sales	0 0 0 0 0 0 0.04 0 0 0.02 0 0 0.07	-
Net income	-137M -14.42M -12.45M -11.68M -10.64M -20M -1.38B -20.28M -53.65M -691M -54.14M -52.96M -2.3B	-65.17M -6.86M -5.93M -5.56M -5.06M -9.52M -656M -9.65M -25.54M -329M -25.77M -25.21M -1.09B
Net Debt	-223M -23.53M -20.31M -19.06M -17.36M -32.64M -2.25B -33.09M -87.54M -1.13B -88.34M -86.42M -3.75B	-144M -15.17M -13.09M -12.28M -11.19M -21.04M -1.45B -21.33M -56.43M -727M -56.95M -55.71M -2.42B